High rate of abnormal blood values and vascular complications before diagnosis of myeloproliferative neoplasms

Anneli Enblom‐Larsson(Umeå University), Björn Andréasson(NU Hospital Group), François Girodon(Inserm), Jennifer Tetu(CHU Dijon Bourgogne), Emma Lindskog(NU Hospital Group), Hans Carl Hasselbalch(Zealand University Hospital), Marie Bak(Zealand University Hospital), Ditte Stampe Hersby(Copenhagen University Hospital)

European Journal of Internal Medicine

April 11, 2015

10.1016/j.ejim.2015.03.009

Cited by 59

Related Papers

Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs

|Journal of Clinical Oncology|2012|461

Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study

|The Lancet Haematology|2020|351

The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients

|Blood|2011|340

A prognostic model to predict survival in 867 World Health Organization–defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment

|Blood|2012|270

Treatment-Related Risk Factors for Transformation to Acute Myeloid Leukemia and Myelodysplastic Syndromes in Myeloproliferative Neoplasms

|Journal of Clinical Oncology|2011|244